Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page
- Check3 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4. This signals a backend/documentation update without changing the displayed study details.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision label was updated to v3.6.3, signifying a small documentation/versioning update rather than a substantive change to the study details.SummaryDifference0.0%

- Check32 days agoChange DetectedThe revision label on the page has been updated to v3.6.2, replacing the previous v3.6.0. This represents a small backend or formatting update without impacting the study information presented.SummaryDifference0.0%

- Check46 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment notice states the study is no longer looking for participants. The Intervention/Treatment heading formatting was adjusted and the revision label updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check53 days agoChange DetectedThe page shows a revision tag updated from v3.5.4 to v3.5.5, signaling a newer release version of the page. This update does not modify the study details or visible content.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, representing a minor update to the page's revision label. It does not modify the study content or eligibility details on the entry.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.